Roche Rolls Out 3 Next-Gen COVID-19 Tests in Europe
By Sam Brusco, Associate Editor | 10.12.22
The new test configurations use an improved capture antibody and add new digital data-sharing capabilities.
Roche has launched its next-generation portfolio of SARS-CoV-2 rapid antigen tests (2.0) for self-testing and professional use in countries that accept the CE mark. Distribution is expected to begin in the upcoming weeks.
The three new test configurations use an improved capture antibody and add new digital data-sharing capabilities. The tests use nasopharyngeal and nasal swabs and deliver results in as few as 15 minutes.
“The continued evolution of the SARS-CoV-2 virus and COVID-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible,” Thomas Schinecker, CEO of Roche Diagnostics told the press. “As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio. These tests are ready to support global society as we navigate this next phase of the pandemic.”
The three tests set to launch are:
The portfolio will be released in partnership with SD Biosensor, with whom Roche has a global distribution agreement and previously rolled out a range of rapid antigen and antibody tests in over 50 countries.
The three new test configurations use an improved capture antibody and add new digital data-sharing capabilities. The tests use nasopharyngeal and nasal swabs and deliver results in as few as 15 minutes.
“The continued evolution of the SARS-CoV-2 virus and COVID-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible,” Thomas Schinecker, CEO of Roche Diagnostics told the press. “As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio. These tests are ready to support global society as we navigate this next phase of the pandemic.”
The three tests set to launch are:
- SARS-CoV-2 Rapid Antigen Test 2.0 (nasopharyngeal sampling)
- SARS-CoV-2 Rapid Antigen Test 2.0 Nasal (nasal sampling)
- SARS-CoV-2 Antigen Self-Test Nasal (nasal sampling)
The portfolio will be released in partnership with SD Biosensor, with whom Roche has a global distribution agreement and previously rolled out a range of rapid antigen and antibody tests in over 50 countries.
